Profit at big-cap biotech stock Biogen Idec (BIIB) has risen every year since 1998, even climbing through recessions, thanks to strong drug offerings. The trend is expected to continue, with profit this year expected to rise 29% to $11.53 a share, followed by a 25% gain in 2015. Biogen develops drugs for diseases such as multiple sclerosis, cancer and arthritis.